Robert G Gish, MD
Gastroenterology · Folsom
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 7 carriers
- Offices
- 2
Offices
2 locations · Gastroenterology Medical Clinic · Providence Medical Foundation
Hospitals listed: Providence Santa Rosa Memorial Hospital. That is not proof they admit you there this week.
Plans that list them
24 plans · 7 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gish’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G45632 · Current
Licensed to practise in California · since 1981 · expires 2028-09-30 · University of Kansas School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Santa Rosa Memorial HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.375, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Santa Rosa Memorial Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.375 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.19 (0.26 to 2.13) · 1,736 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.76 (0.48 to 1.03) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.27 (137.92 to 224.62) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.8 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 530 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.2 · 448 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.3 · 245 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 2,733 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 8,115 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,057 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.37 (0.56 to 4.18) · 2,186 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.59 (0.1 to 3.08) · 772 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.27 (0.9 to 3.63) · 1,999 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.74 (0.06 to 11.42) · 810 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.04 (0.53 to 7.55) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.8 (0.38 to 3.21) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1) · 7,051 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.3 · 77 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.915 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.552 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.297 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.353 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 288 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 489 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 0.4 · 259 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 580 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.5 · 456 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.2 · 431 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.4 (4.9 to 8.3) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.3 (8.2 to 12.7) · 584 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 72 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.4 · 64 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.5 (10.8 to 16.7) · 2,810 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 780 cases | No different | Jan 2024 – Dec 2024 |
What patients said (473 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$43,447
Medicare paid this office $43,447 for 139 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 88 | $23,117 | $148 |
| New patient visit (60+ min) | 49 | $8,633 | $176 |
| Ultrasound scan of organ tissue for measuring elasticity | 20 | $1,338 | $67 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,293 | $72 |
| Return visit (30+ min) | 11 | $1,158 | $105 |
Who their Medicare patients are
139 Original Medicare patients in 2024. Average age 73 · Women 60% · Also on Medicaid 34% · Health risk score 1.75. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 35% · Chronic kidney disease 32% · Coronary heart disease 29% · Depression 22% · Heart failure 19% · Cancer 18% · COPD 17% · Atrial fibrillation 15% · Stroke 8%.
The office billed $145,064, Medicare allowed $57,901 and paid $43,447; for 435 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 139 | 435 | 73 | 1.75 | $145,064 | $43,447 |
| 2023 | 126 | 339 | 73 | 1.57 | $115,796 | $42,915 |
| 2022 | 82 | 279 | 74 | 1.58 | $73,902 | $30,137 |
| 2021 | 60 | 246 | 72 | 1.61 | $53,308 | $24,011 |
| 2020 | 23 | 38 | 70 | 1.67 | $11,283 | $3,798 |
| 2019 | 63 | 75 | 68 | 3.22 | $66,837 | $7,338 |
| 2018 | 137 | 199 | 68 | 2.33 | $174,683 | $21,961 |
| 2017 | 136 | 198 | 67 | 2.46 | $132,492 | $23,808 |
| 2016 | 118 | 164 | 68 | 2.14 | $92,437 | $19,162 |
| 2015 | 79 | 105 | 66 | 2.05 | $62,365 | $14,359 |
| 2013 | 133 | 276 | 65 | 2.57 | $103,292 | $24,242 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Long return visit (40+ min) | 89 | $27,719 | $147 |
| New patient visit (60+ min) | 42 | $7,313 | $174 |
| Telephone medical discussion with physician, 21-30 minutes | 17 | $1,882 | $94 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 16 | $651 | $27 |
| Measurement of liver stiffness | 11 | $300 | $27 |
2022: 3 services
| Long return visit (40+ min) | 62 | $20,274 | $149 |
| New patient visit (60+ min) | 32 | $5,634 | $176 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 57 | $2,624 | $28 |
2021: 3 services
| Long return visit (40+ min) | 44 | $14,851 | $155 |
| New patient visit (60+ min) | 33 | $5,603 | $170 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 47 | $3,285 | $29 |
2019: 2 services
| Long return visit (40+ min) | 46 | $4,778 | $88 |
| New patient visit (60+ min) | 20 | $2,424 | $121 |
2018: 2 services
| Long return visit (40+ min) | 91 | $12,268 | $95 |
| New patient visit (60+ min) | 67 | $9,402 | $140 |
2017: 2 services
| New patient visit (60+ min) | 98 | $13,884 | $142 |
| Long return visit (40+ min) | 62 | $9,839 | $99 |
2016: 2 services
| New patient visit (60+ min) | 87 | $12,026 | $138 |
| Long return visit (40+ min) | 45 | $6,646 | $92 |
2015: 3 services
| New patient visit (60+ min) | 50 | $8,046 | $161 |
| New patient visit (60+ min) | 24 | $3,234 | $135 |
| Long return visit (40+ min) | 11 | $1,245 | $89 |
2013: 4 services
| Long return visit (40+ min) | 59 | $7,298 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $5,135 | $77 |
| Return visit (30+ min) | 30 | $2,810 | $85 |
| New patient visit (60+ min) | 23 | $2,428 | $106 |
Medicaid work
$68,139 in 2024
Medicaid paid $68,139 for 1,050 billed services this clinician did in 2024, up to 41 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 281 | $61,934 |
| Short return visit (20+ min) | 480 | $5,575 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 135 | $533 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 35 | $98 |
| COMPREHENSIVE METABOLIC PANEL | 13 | $0 |
| Glutamyltransferase, gamma (GGT) | 106 | $0 |
| 2024 | 1,050 | 6 | 41 | $68,139 |
| 2023 | 1,137 | 7 | 41 | $66,207 |
| 2022 | 956 | 6 | 35 | $60,850 |
| 2021 | 1,229 | 4 | 40 | $76,244 |
| 2020 | 963 | 8 | 31 | $56,784 |
| 2019 | 829 | 8 | 94 | $82,824 |
| 2018 | 2,391 | 7 | 112 | $325,013 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 290 | $60,838 |
| Short return visit (20+ min) | 469 | $4,319 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 214 | $758 |
| Long return visit (40+ min) | 24 | $255 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 16 | $38 |
| COMPREHENSIVE METABOLIC PANEL | 12 | $0 |
| Glutamyltransferase, gamma (GGT) | 112 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 274 | $56,938 |
| Short return visit (20+ min) | 451 | $3,360 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 135 | $488 |
| Long return visit (40+ min) | 12 | $63 |
| Glutamyltransferase, gamma (GGT) | 72 | $0 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 12 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 385 | $73,667 |
| Short return visit (20+ min) | 564 | $2,376 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 96 | $186 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 184 | $15 |
2020
| Clinic visit/encounter, all-inclusive | 294 | $55,543 |
| Long return visit (40+ min) | 181 | $950 |
| Short return visit (20+ min) | 198 | $168 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 21-30 minutes of medical discussion | 158 | $75 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 80 | $49 |
| COMPREHENSIVE METABOLIC PANEL | 17 | $0 |
| Glutamyltransferase, gamma (GGT) | 17 | $0 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 18 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 382 | $79,648 |
| Long return visit (40+ min) | 129 | $2,289 |
| Return visit (30+ min) | 125 | $800 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 128 | $87 |
| COMPREHENSIVE METABOLIC PANEL | 13 | $0 |
| Measurement of direct bilirubin | 13 | $0 |
| Measurement of iron | 25 | $0 |
| Oncoprotein; des-gamma-carboxy-prothrombin (DCP) | 14 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 1,545 | $318,790 |
| Return visit (30+ min) | 637 | $4,447 |
| Long return visit (40+ min) | 109 | $1,758 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 63 | $18 |
| Glutamyltransferase, gamma (GGT) | 12 | $0 |
| Measurement of iron | 13 | $0 |
| Rheumatoid factor level | 12 | $0 |
Drugs they prescribed that Part D paid
$501,066
Pharmacies billed $501,066 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 468) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
333 generic and 135 brand-name prescriptions · $501,066 in drug cost · 21 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 64 | $101,433 | $1,585 |
| Sofosbuvir-Velpatasvir | 11 | $86,799 | $7,891 |
| Xifaxan | 16 | $75,740 | $4,734 |
| Ursodiol | 104 | $14,387 | $138 |
| Mycophenolate Mofetil | 47 | $11,735 | $250 |
See all 13 drugs
| Vemlidy | 64 | $101,433 | $1,585 |
| Sofosbuvir-Velpatasvir | 11 | $86,799 | $7,891 |
| Xifaxan | 16 | $75,740 | $4,734 |
| Ursodiol | 104 | $14,387 | $138 |
| Mycophenolate Mofetil | 47 | $11,735 | $250 |
| Eliquis | 12 | $8,459 | $705 |
| Entecavir | 23 | $4,209 | $183 |
| Tacrolimus | 12 | $1,529 | $127 |
| Atorvastatin | 67 | $753 | $11 |
| Spironolactone | 11 | $289 | $26 |
| Carvedilol | 12 | $153 | $13 |
| Gabapentin | 14 | $73 | $5 |
| Furosemide | 17 | $55 | $3 |
Year by year
| 2024 | 468 | 102 | 0% (0) | 29% | $501,066 |
| 2023 | 373 | 80 | 0% (0) | 24% | $325,491 |
| 2022 | 261 | 49 | 0% (0) | 25% | $253,150 |
| 2021 | 149 | 29 | 0% (0) | 21% | $195,983 |
| 2020 | 36 | 16 | 0% (0) | 31% | $58,025 |
| 2019 | 127 | 26 | 0% (0) | 30% | $361,480 |
| 2018 | 192 | 31 | 0% (0) | 38% | $860,277 |
| 2017 | 190 | 39 | 0% (0) | 49% | $918,807 |
| 2016 | 218 | 44 | None | 33% | $1,278,920 |
| 2015 | 51 | 13 | None | 51% | $526,370 |
| 2014 | 37 | 15 | 0% (0) | 46% | $17,330 |
| 2013 | 364 | 54 | None | None | $125,702 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Vemlidy | 47 | $69,769 | $1,484 |
| Ursodiol | 81 | $19,329 | $239 |
| Mycophenolate Mofetil | 40 | $12,633 | $316 |
| Entecavir | 13 | $7,348 | $565 |
| Eliquis | 11 | $6,592 | $599 |
| Tacrolimus | 13 | $1,882 | $145 |
| Atorvastatin | 72 | $1,177 | $16 |
| Furosemide | 14 | $71 | $5 |
2022: 5 drugs
| Vemlidy | 33 | $45,538 | $1,380 |
| Ursodiol | 58 | $17,818 | $307 |
| Mycophenolate Mofetil | 48 | $10,014 | $209 |
| Atorvastatin | 31 | $313 | $10 |
| Furosemide | 16 | $58 | $4 |
2021: 4 drugs
| Vemlidy | 12 | $15,578 | $1,298 |
| Ursodiol | 37 | $9,285 | $251 |
| Mycophenolate Mofetil | 17 | $2,082 | $122 |
| Hydroxyzine | 12 | $141 | $12 |
2019: 2 drugs
| Ursodiol | 42 | $9,515 | $227 |
| Mycophenolate Mofetil | 25 | $2,159 | $86 |
2018: 5 drugs
| Mavyret | 12 | $156,169 | $13,014 |
| Ursodiol | 57 | $26,853 | $471 |
| Ribavirin | 14 | $1,584 | $113 |
| Mycophenolate Mofetil | 25 | $1,449 | $58 |
| Metoprolol | 12 | $44 | $4 |
2017: 6 drugs
| Epclusa | 20 | $505,203 | $25,260 |
| Ocaliva | 21 | $139,959 | $6,665 |
| Ursodiol | 35 | $17,366 | $496 |
| Vemlidy | 11 | $11,282 | $1,026 |
| Mycophenolate Mofetil | 18 | $1,557 | $86 |
| Ribavirin | 14 | $862 | $62 |
2016: 9 drugs
| Harvoni | 11 | $346,516 | $31,501 |
| Sovaldi | 12 | $336,121 | $28,010 |
| Valganciclovir | 12 | $34,673 | $2,889 |
| Ursodiol | 45 | $18,876 | $419 |
| Budesonide Ec | 14 | $6,892 | $492 |
| Tacrolimus | 14 | $1,791 | $128 |
| Ribasphere | 11 | $881 | $80 |
| Mycophenolate Mofetil | 18 | $799 | $44 |
| Pravastatin | 11 | $196 | $18 |
2013: 15 drugs
| Xifaxan | 30 | $42,093 | $1,403 |
| Viread | 18 | $18,844 | $1,047 |
| Baraclude | 11 | $11,376 | $1,034 |
| Tacrolimus | 27 | $5,046 | $187 |
| Ursodiol | 26 | $4,825 | $186 |
| Nexium | 16 | $3,410 | $213 |
| Mycophenolate Mofetil | 16 | $1,656 | $104 |
| Lactulose | 20 | $315 | $16 |
| Azathioprine | 13 | $198 | $15 |
| Pravastatin | 15 | $154 | $10 |
| Prednisone | 13 | $113 | $9 |
| Omeprazole | 12 | $107 | $9 |
| Amlodipine Besylate | 12 | $78 | $6 |
| Furosemide | 16 | $71 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $42 | $4 |
Money from drug and device companies
$353,789 in 2025
| 2025 | 19 | 300 | $309,109 | $353,789 |
| 2024 | 17 | 273 | $354,422 | $415,107 |
| 2023 | 20 | 288 | $256,382 | $310,381 |
| 2022 | 17 | 206 | $181,415 | $206,343 |
| 2021 | 11 | 104 | $122,310 | $127,973 |
| 2020 | 11 | 118 | $152,524 | $168,217 |
| 2019 | 16 | 269 | $259,179 | $306,767 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $117,336 | 106 payments
|
| Ipsen Biopharmaceuticals | Iqirvo | $83,211 | 40 payments
|
| Mirum Pharmaceuticals | Livmarli | $43,203 | 62 payments
|
| Gilead Sciences | Livdelzi | $39,601 | 42 payments
|
| GlaxoSmithKline | None | $33,417 | 13 payments
|
| Intercept Pharmaceuticals | Ocaliva | $16,672 | 8 payments
|
See all 300 published payments
| Mirum Pharmaceuticals | Consulting · 2025-12-19 | Livmarli | $385 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-12-17 | Bylvay | $2,754 |
| Madrigal Pharmaceuticals | Meals · 2025-12-16 | Rezdiffra | $127 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-12-16 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Travel · 2025-12-16 | Rezdiffra | $46 |
| Madrigal Pharmaceuticals | Meals · 2025-12-15 | Rezdiffra | $101 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-12-15 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Meals · 2025-12-15 | Rezdiffra | $36 |
| Madrigal Pharmaceuticals | Travel · 2025-12-15 | Rezdiffra | $326 |
| Madrigal Pharmaceuticals | Travel · 2025-12-15 | Rezdiffra | $212 |
| Madrigal Pharmaceuticals | Travel · 2025-12-15 | Rezdiffra | $149 |
| Mirum Pharmaceuticals | Meals · 2025-12-13 | Livmarli | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-12-13 | Rezdiffra | $83 |
| Madrigal Pharmaceuticals | Meals · 2025-12-13 | Rezdiffra | $64 |
| GlaxoSmithKline | Consulting · 2025-12-12 | None | $1,200 |
| Gilead Sciences | Paid to speak or teach · 2025-12-11 | Livdelzi | $3,790 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-12-10 | Bylvay | $1,377 |
| Gilead Sciences | Travel · 2025-12-09 | Vemlidy | $125 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-12-09 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Meals · 2025-12-09 | Rezdiffra | $18 |
| Madrigal Pharmaceuticals | Meals · 2025-12-07 | Rezdiffra | $137 |
| Madrigal Pharmaceuticals | Meals · 2025-12-07 | Rezdiffra | $11 |
| Gilead Sciences | Travel · 2025-12-05 | Livdelzi | $1,242 |
| Gilead Sciences | Paid to speak or teach · 2025-12-04 | None | $6,440 |
| Gilead Sciences | Meals · 2025-12-04 | None | $25 |
| Gilead Sciences | Travel · 2025-12-03 | Livdelzi | $390 |
| Gilead Sciences | Travel · 2025-12-02 | Livdelzi | $418 |
| Gilead Sciences | Meals · 2025-12-02 | Livdelzi | $134 |
| Gilead Sciences | Meals · 2025-12-02 | None | $21 |
| Gilead Sciences | Paid to speak or teach · 2025-11-24 | Vemlidy | $3,790 |
| Gilead Sciences | Education · 2025-11-24 | None | $20 |
| Mirum Pharmaceuticals | Meals · 2025-11-24 | Livmarli | $11 |
| Madrigal Pharmaceuticals | Meals · 2025-11-24 | Rezdiffra | $42 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-11-21 | Entyvio | $29 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-11-20 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Meals · 2025-11-20 | Rezdiffra | $128 |
| Madrigal Pharmaceuticals | Travel · 2025-11-20 | Rezdiffra | $389 |
| Madrigal Pharmaceuticals | Travel · 2025-11-20 | Rezdiffra | $145 |
| Orphalan | Honoraria · 2025-11-19 | Cuvrior | $3,000 |
| Gilead Sciences | Meals · 2025-11-18 | Vemlidy | $143 |
| Novo Nordisk | Meals · 2025-11-13 | Wegovy | $19 |
| Mallinckrodt Hospital Products | Travel · 2025-11-12 | Terlivaz | $164 |
| Mallinckrodt Hospital Products | Meals · 2025-11-12 | Terlivaz | $34 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-11-12 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-11-12 | Rezdiffra | $301 |
| Madrigal Pharmaceuticals | Meals · 2025-11-12 | Rezdiffra | $144 |
| Madrigal Pharmaceuticals | Travel · 2025-11-12 | Rezdiffra | $277 |
| Madrigal Pharmaceuticals | Travel · 2025-11-12 | Rezdiffra | $208 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-11-11 | None | $4,800 |
| Ipsen Biopharmaceuticals | Travel · 2025-11-11 | None | $399 |
| Mirum Pharmaceuticals | Consulting · 2025-11-09 | Livmarli | $3,080 |
| GlaxoSmithKline | Consulting · 2025-11-07 | None | $800 |
| Gilead Sciences | Meals · 2025-11-07 | None | $137 |
| Abbvie | Meals · 2025-10-29 | Creon | $18 |
| GlaxoSmithKline | Travel · 2025-10-28 | None | $555 |
| GlaxoSmithKline | Travel · 2025-10-28 | None | $431 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-10-28 | Terlivaz | $6,900 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $138 |
| Mirum Pharmaceuticals | Meals · 2025-10-28 | Livmarli | $126 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $131 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $638 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $152 |
| Mirum Pharmaceuticals | Meals · 2025-10-28 | Livmarli | $27 |
| Mirum Pharmaceuticals | Consulting · 2025-10-28 | Livmarli | $3,080 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $128 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $28 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $65 |
| Mirum Pharmaceuticals | Consulting · 2025-10-28 | Livmarli | $1,540 |
| Mirum Pharmaceuticals | Travel · 2025-10-28 | Livmarli | $383 |
| GlaxoSmithKline | Consulting · 2025-10-24 | None | $8,000 |
| Abbvie | Meals · 2025-10-24 | Creon | $18 |
| Mallinckrodt Hospital Products | Travel · 2025-10-24 | Terlivaz | $309 |
| Gilead Sciences | Consulting · 2025-10-24 | None | $2,040 |
| Gilead Sciences | Travel · 2025-10-24 | None | $69 |
| Gilead Sciences | Travel · 2025-10-24 | None | $13 |
| Mallinckrodt Hospital Products | Travel · 2025-10-23 | Terlivaz | $613 |
| Mallinckrodt Hospital Products | Travel · 2025-10-23 | Terlivaz | $349 |
| Mallinckrodt Hospital Products | Meals · 2025-10-23 | Terlivaz | $146 |
| Abbvie | Meals · 2025-10-16 | Rinvoq | $30 |
| Madrigal Pharmaceuticals | Meals · 2025-10-15 | Rezdiffra | $74 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-10-15 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-10-15 | Rezdiffra | $452 |
| Madrigal Pharmaceuticals | Travel · 2025-10-15 | Rezdiffra | $220 |
| Madrigal Pharmaceuticals | Travel · 2025-10-15 | Rezdiffra | $525 |
| Gilead Sciences | Travel · 2025-10-10 | None | $60 |
| Gilead Sciences | Meals · 2025-10-10 | None | $60 |
| Gilead Sciences | Meals · 2025-10-10 | None | $27 |
| Gilead Sciences | Meals · 2025-10-10 | None | $17 |
| Gilead Sciences | Meals · 2025-10-10 | None | $17 |
| Neurocrine BioSciences | Consulting · 2025-10-02 | Ingrezza | $2,750 |
| Ardelyx | Meals · 2025-10-02 | Ibsrela | $30 |
| Orphalan | Meals · 2025-09-25 | Cuvrior | $53 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-09-23 | Iqirvo | $1,377 |
| Abbvie | Meals · 2025-09-22 | Mavyret | $18 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-20 | Iqirvo | $507 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-20 | Iqirvo | $170 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-20 | Iqirvo | $71 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-09-20 | Iqirvo | $2,754 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-19 | Iqirvo | $1,238 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-19 | Iqirvo | $1,151 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-19 | Iqirvo | $200 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-09-19 | Iqirvo | $7,803 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-11 | Iqirvo | $193 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-11 | Iqirvo | $62 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-11 | Iqirvo | $122 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-09-11 | Iqirvo | $5,967 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-10 | Iqirvo | $239 |
| Ipsen Biopharmaceuticals | Travel · 2025-09-10 | Iqirvo | $1,214 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-10 | Iqirvo | $129 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-09-10 | Iqirvo | $5,967 |
| Mirum Pharmaceuticals | Consulting · 2025-09-10 | Livmarli | $1,155 |
| Madrigal Pharmaceuticals | Meals · 2025-09-09 | Rezdiffra | $121 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-09-09 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Meals · 2025-09-09 | Rezdiffra | $8 |
| Madrigal Pharmaceuticals | Travel · 2025-09-09 | Rezdiffra | $239 |
| Madrigal Pharmaceuticals | Travel · 2025-09-09 | Rezdiffra | $257 |
| Madrigal Pharmaceuticals | Travel · 2025-09-09 | Rezdiffra | $1,852 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-09-09 | Rezdiffra | $2,468 |
| Gilead Sciences | Meals · 2025-09-04 | None | $25 |
| Mirum Pharmaceuticals | Travel · 2025-09-03 | Livmarli | $54 |
| Mirum Pharmaceuticals | Travel · 2025-09-03 | Livmarli | $35 |
| Mirum Pharmaceuticals | Travel · 2025-09-03 | Livmarli | $114 |
| Mirum Pharmaceuticals | Meals · 2025-09-03 | Livmarli | $123 |
| Mirum Pharmaceuticals | Consulting · 2025-09-03 | Livmarli | $3,900 |
| Mirum Pharmaceuticals | Consulting · 2025-09-03 | Livmarli | $1,300 |
| Mirum Pharmaceuticals | Meals · 2025-09-03 | Livmarli | $19 |
| Mirum Pharmaceuticals | Travel · 2025-09-03 | Livmarli | $128 |
| Mirum Pharmaceuticals | Travel · 2025-09-03 | Livmarli | $598 |
| Mirum Pharmaceuticals | Travel · 2025-09-03 | Livmarli | $68 |
| GlaxoSmithKline | Consulting · 2025-09-02 | None | $4,000 |
| Ipsen Biopharmaceuticals | Meals · 2025-09-02 | Iqirvo | $25 |
| Intercept Pharmaceuticals | Consulting · 2025-09-02 | Ocaliva | $1,995 |
| Eton Pharmaceuticals | Meals · 2025-08-30 | Galzin | $22 |
| Mirum Pharmaceuticals | Consulting · 2025-08-27 | Livmarli | $1,925 |
| Mirum Pharmaceuticals | Meals · 2025-08-27 | Livmarli | $138 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-08-25 | Xifaxan | $25 |
| Madrigal Pharmaceuticals | Meals · 2025-08-21 | Rezdiffra | $112 |
| Madrigal Pharmaceuticals | Meals · 2025-08-21 | Rezdiffra | $49 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-08-21 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-08-21 | Rezdiffra | $149 |
| Madrigal Pharmaceuticals | Travel · 2025-08-21 | Rezdiffra | $370 |
| Madrigal Pharmaceuticals | Travel · 2025-08-21 | Rezdiffra | $267 |
| Madrigal Pharmaceuticals | Meals · 2025-08-20 | Rezdiffra | $59 |
| Mirum Pharmaceuticals | Meals · 2025-08-18 | Livmarli | $22 |
| Lilly USA | Meals · 2025-08-08 | Omvoh | $19 |
| Mirum Pharmaceuticals | Travel · 2025-08-06 | Livmarli | $52 |
| Mirum Pharmaceuticals | Travel · 2025-08-06 | Livmarli | $25 |
| Mirum Pharmaceuticals | Consulting · 2025-08-06 | Livmarli | $1,540 |
| Mirum Pharmaceuticals | Travel · 2025-08-06 | Livmarli | $20 |
| Mirum Pharmaceuticals | Meals · 2025-08-06 | Livmarli | $19 |
| Mirum Pharmaceuticals | Meals · 2025-08-06 | Livmarli | $128 |
| Mirum Pharmaceuticals | Consulting · 2025-08-06 | Livmarli | $3,080 |
| Mirum Pharmaceuticals | Travel · 2025-08-06 | Livmarli | $31 |
| Mirum Pharmaceuticals | Travel · 2025-08-06 | Livmarli | $239 |
| Mirum Pharmaceuticals | Travel · 2025-08-06 | Livmarli | $218 |
| Gilead Sciences | Travel · 2025-08-05 | Livdelzi | $89 |
| Gilead Sciences | Meals · 2025-08-05 | Livdelzi | $34 |
| GlaxoSmithKline | Consulting · 2025-08-04 | None | $3,200 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $117 |
| Mirum Pharmaceuticals | Consulting · 2025-07-30 | Livmarli | $3,080 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $16 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $57 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $27 |
| Mirum Pharmaceuticals | Consulting · 2025-07-30 | Livmarli | $5,775 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $74 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $782 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $25 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $32 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $28 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $22 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $18 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $127 |
| Mirum Pharmaceuticals | Meals · 2025-07-30 | Livmarli | $68 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $40 |
| Mirum Pharmaceuticals | Travel · 2025-07-30 | Livmarli | $713 |
| Intercept Pharmaceuticals | Paid to speak or teach · 2025-07-30 | Ocaliva | $2,170 |
| Gilead Sciences | Paid to speak or teach · 2025-07-24 | Livdelzi | $6,440 |
| Abbvie | Meals · 2025-07-22 | Mavyret | $10 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-07-22 | Bylvay | $2,754 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $38 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $95 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $57 |
| Madrigal Pharmaceuticals | Meals · 2025-07-19 | Rezdiffra | $70 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $90 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $496 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $244 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-07-18 | Rezdiffra | $5,288 |
| Madrigal Pharmaceuticals | Travel · 2025-07-18 | Rezdiffra | $159 |
| Madrigal Pharmaceuticals | Meals · 2025-07-18 | Rezdiffra | $196 |
| GlaxoSmithKline | Meals · 2025-07-16 | None | $31 |
| GlaxoSmithKline | Consulting · 2025-07-15 | None | $1,200 |
| Abbvie | Meals · 2025-07-15 | Mavyret | $37 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-07-15 | Iqirvo | $1,377 |
| Gilead Sciences | Travel · 2025-07-14 | Livdelzi | $1,178 |
| Gilead Sciences | Travel · 2025-07-10 | Livdelzi | $193 |
| Gilead Sciences | Meals · 2025-07-10 | Livdelzi | $119 |
| Madrigal Pharmaceuticals | Meals · 2025-07-08 | Rezdiffra | $29 |
| Mirum Pharmaceuticals | Consulting · 2025-07-07 | Livmarli | $1,925 |
| Madrigal Pharmaceuticals | Meals · 2025-06-25 | Rezdiffra | $18 |
| Gilead Sciences | Travel · 2025-06-19 | Livdelzi | $37 |
| Gilead Sciences | Travel · 2025-06-19 | Livdelzi | $18 |
| Gilead Sciences | Meals · 2025-06-19 | Livdelzi | $59 |
| Mirum Pharmaceuticals | Consulting · 2025-06-18 | Livmarli | $1,925 |
| Mirum Pharmaceuticals | Consulting · 2025-06-17 | Livmarli | $1,925 |
| Gilead Sciences | Travel · 2025-06-04 | Livdelzi | $372 |
| Gilead Sciences | Meals · 2025-06-04 | None | $33 |
| GlaxoSmithKline | Consulting · 2025-06-03 | None | $1,600 |
| Ipsen Biopharmaceuticals | Travel · 2025-05-31 | Iqirvo | $203 |
| Ipsen Biopharmaceuticals | Travel · 2025-05-31 | Iqirvo | $830 |
| Ipsen Biopharmaceuticals | Meals · 2025-05-31 | Iqirvo | $261 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-05-31 | Iqirvo | $10,560 |
| Madrigal Pharmaceuticals | Consulting · 2025-05-27 | None | $6,210 |
| Gilead Sciences | Meals · 2025-05-21 | None | $32 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-05-21 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-05-21 | Rezdiffra | $854 |
| Madrigal Pharmaceuticals | Travel · 2025-05-21 | Rezdiffra | $543 |
| Madrigal Pharmaceuticals | Travel · 2025-05-21 | Rezdiffra | $451 |
| Madrigal Pharmaceuticals | Travel · 2025-05-21 | Rezdiffra | $164 |
| Madrigal Pharmaceuticals | Meals · 2025-05-21 | Rezdiffra | $122 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-05-20 | Iqirvo | $5,049 |
| Ipsen Biopharmaceuticals | Meals · 2025-05-20 | Iqirvo | $139 |
| Gilead Sciences | Paid to speak or teach · 2025-05-19 | Livdelzi | $6,440 |
| Gilead Sciences | Travel · 2025-05-15 | Livdelzi | $981 |
| Gilead Sciences | Travel · 2025-05-13 | Livdelzi | $680 |
| Gilead Sciences | Travel · 2025-05-13 | Livdelzi | $317 |
| Gilead Sciences | Meals · 2025-05-13 | Livdelzi | $113 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-05-09 | None | $537 |
| GlaxoSmithKline | Consulting · 2025-05-07 | None | $6,400 |
| Intercept Pharmaceuticals | Consulting · 2025-05-02 | Ocaliva | $570 |
| Intercept Pharmaceuticals | Consulting · 2025-05-02 | Ocaliva | $570 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-04-15 | Bylvay | $2,880 |
| Madrigal Pharmaceuticals | Travel · 2025-04-08 | Rezdiffra | $696 |
| Madrigal Pharmaceuticals | Travel · 2025-04-08 | Rezdiffra | $292 |
| Madrigal Pharmaceuticals | Travel · 2025-04-08 | Rezdiffra | $240 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-04-08 | Rezdiffra | $2,468 |
| Madrigal Pharmaceuticals | Meals · 2025-04-08 | Rezdiffra | $137 |
| Madrigal Pharmaceuticals | Travel · 2025-04-08 | Rezdiffra | $60 |
| Madrigal Pharmaceuticals | Meals · 2025-04-08 | Rezdiffra | $48 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-04-08 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-04-08 | Rezdiffra | $1,395 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-04-07 | Iqirvo | $7,803 |
| Ipsen Biopharmaceuticals | Travel · 2025-04-07 | Iqirvo | $47 |
| Ipsen Biopharmaceuticals | Meals · 2025-04-07 | Iqirvo | $186 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-03-24 | Bylvay | $4,590 |
| Abbvie | Meals · 2025-03-20 | Mavyret | $40 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-03-20 | Terlivaz | $1,380 |
| Gilead Sciences | Meals · 2025-03-19 | None | $112 |
| Gilead Sciences | Meals · 2025-03-19 | None | $102 |
| GlaxoSmithKline | Consulting · 2025-03-18 | None | $5,600 |
| Mirum Pharmaceuticals | Meals · 2025-03-17 | Livmarli | $16 |
| Janssen Biotech | Meals · 2025-03-13 | Tremfya | $29 |
| Mirum Pharmaceuticals | Consulting · 2025-03-12 | Livmarli | $1,540 |
| Madrigal Pharmaceuticals | Meals · 2025-03-11 | Rezdiffra | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-03-11 | Rezdiffra | $108 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-03-11 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-03-11 | Rezdiffra | $412 |
| Madrigal Pharmaceuticals | Travel · 2025-03-11 | Rezdiffra | $430 |
| Madrigal Pharmaceuticals | Travel · 2025-03-11 | Rezdiffra | $443 |
| Madrigal Pharmaceuticals | Meals · 2025-03-07 | Rezdiffra | $21 |
| Intercept Pharmaceuticals | Consulting · 2025-03-07 | Ocaliva | $3,420 |
| Intercept Pharmaceuticals | Consulting · 2025-03-07 | Ocaliva | $3,420 |
| Madrigal Pharmaceuticals | Meals · 2025-03-05 | Rezdiffra | $85 |
| Madrigal Pharmaceuticals | Meals · 2025-03-05 | Rezdiffra | $146 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-03-05 | Rezdiffra | $279 |
| Madrigal Pharmaceuticals | Travel · 2025-03-05 | Rezdiffra | $116 |
| Madrigal Pharmaceuticals | Travel · 2025-03-05 | Rezdiffra | $148 |
| Madrigal Pharmaceuticals | Meals · 2025-02-27 | Rezdiffra | $109 |
| Madrigal Pharmaceuticals | Meals · 2025-02-20 | Rezdiffra | $17 |
| Gilead Sciences | Consulting · 2025-02-13 | None | $3,250 |
| Ipsen Biopharmaceuticals | Honoraria · 2025-02-11 | None | $3,320 |
| Ipsen Biopharmaceuticals | Honoraria · 2025-02-11 | None | $1,868 |
| Roche Diagnostics International | Consulting · 2025-02-10 | None | $287 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-02-08 | Iqirvo | $2,754 |
| GlaxoSmithKline | Consulting · 2025-02-07 | None | $400 |
| Mallinckrodt Hospital Products | Paid to speak or teach · 2025-02-06 | Terlivaz | $3,450 |
| Ipsen Biopharmaceuticals | Meals · 2025-02-04 | Iqirvo | $28 |
| Intercept Pharmaceuticals | Consulting · 2025-02-03 | Ocaliva | $3,720 |
| Intercept Pharmaceuticals | Travel · 2025-02-03 | Ocaliva | $807 |
| Abbvie | Meals · 2025-01-30 | Mavyret | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-01-27 | Rezdiffra | $27 |
| Madrigal Pharmaceuticals | Meals · 2025-01-23 | Rezdiffra | $43 |
| Madrigal Pharmaceuticals | Meals · 2025-01-23 | Rezdiffra | $121 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-01-23 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Travel · 2025-01-23 | Rezdiffra | $42 |
| Madrigal Pharmaceuticals | Travel · 2025-01-23 | Rezdiffra | $129 |
| Madrigal Pharmaceuticals | Travel · 2025-01-23 | Rezdiffra | $930 |
| Madrigal Pharmaceuticals | Travel · 2025-01-23 | Rezdiffra | $138 |
| Madrigal Pharmaceuticals | Meals · 2025-01-22 | Rezdiffra | $91 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-01-22 | Rezdiffra | $4,935 |
| Madrigal Pharmaceuticals | Travel · 2025-01-22 | Rezdiffra | $133 |
| Madrigal Pharmaceuticals | Travel · 2025-01-22 | Rezdiffra | $1,266 |
| Madrigal Pharmaceuticals | Travel · 2025-01-22 | Rezdiffra | $167 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-21 | Iqirvo | $42 |
| Madrigal Pharmaceuticals | Meals · 2025-01-21 | Rezdiffra | $24 |
| Madrigal Pharmaceuticals | Meals · 2025-01-21 | Rezdiffra | $127 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-01-21 | Rezdiffra | $5,993 |
| Madrigal Pharmaceuticals | Travel · 2025-01-21 | Rezdiffra | $29 |
| Madrigal Pharmaceuticals | Travel · 2025-01-21 | Rezdiffra | $108 |
| Madrigal Pharmaceuticals | Travel · 2025-01-21 | Rezdiffra | $266 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-01-17 | Rezdiffra | $2,115 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $415,107
| Intercept Pharmaceuticals | Ocaliva | $134,404 | 53 payments
|
| Gilead Sciences | Vemlidy | $91,662 | 83 payments
|
| Ipsen Biopharmaceuticals | Bylvay | $81,157 | 44 payments
|
| Madrigal Pharmaceuticals | Rezdiffra | $37,106 | 38 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $27,424 | 22 payments
|
| DiaSorin | None | $9,400 | 1 payment
|
| GlaxoSmithKline | None | $8,711 | 9 payments
|
| Ipsen Innovation | Iqirvo | $6,225 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | None | $5,773 | 2 payments
|
| Beckman Coulter | None | $5,625 | 1 payment
|
| Orphalan | Cuvrior | $3,027 | 2 payments
|
| FUJIFILM Healthcare Americas | Utaswako Afp-L3 | $2,800 | 1 payment
|
| Roche Diagnostics International | None | $1,435 | 2 payments
|
| Abbvie | Mavyret | $165 | 3 payments
|
| Mirum Pharmaceuticals | Livmarli | $140 | 6 payments
|
| Janssen Biotech | Tremfya | $29 | 1 payment
|
| Albireo Pharma | Bylvay | $25 | 1 payment
|
2023: $310,381
| Gilead Sciences | Vemlidy | $88,364 | 109 payments
|
| Intercept Pharmaceuticals | Ocaliva | $60,212 | 49 payments
|
| Abbvie | Mavyret | $41,348 | 49 payments
|
| GlaxoSmithKline | None | $36,128 | 6 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $33,907 | 32 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $18,195 | 13 payments
|
| Albireo Pharma | Bylvay | $11,072 | 7 payments
|
| DiaSorin | Various | $9,800 | 1 payment
|
| Roche Diagnostics International | Cobas 6800 System | $3,931 | 4 payments
|
| Ipsen Biopharmaceuticals | None | $3,358 | 2 payments
|
| Hologic | Aixplorer Ultimate | $1,225 | 2 payments
|
| Grifols Shared Services North America | None | $1,025 | 1 payment
|
| Perspectum Diagnostics | Livermultiscan | $750 | 1 payment
|
| Eiger BioPharmaceuticals | Zokinvy | $700 | 1 payment
|
| Orphalan | Cuvrior | $106 | 1 payment
|
| Genentech USA | Tecentriq | $99 | 2 payments
|
| VBI Vaccine (Delaware) | Prehevbrio | $93 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $47 | 2 payments
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $14 | 1 payment
|
| Travere Therapeutics | Cholbam | $7 | 1 payment
|
2022: $206,343
| Gilead Sciences | Vemlidy | $82,655 | 71 payments
|
| Intercept Pharmaceuticals | Ocaliva | $64,972 | 60 payments
|
| Abbvie | Mavyret | $30,486 | 52 payments
|
| GlaxoSmithKline | None | $16,720 | 5 payments
|
| Albireo Pharma | Bylvay | $3,269 | 2 payments
|
| Janssen Global Services | None | $2,145 | 1 payment
|
| Mallinckrodt Hospital Products | Terlivaz | $1,860 | 1 payment
|
| VBI Vaccines (Delaware) | Prehevbrio | $1,600 | 1 payment
|
| FUJIFILM Healthcare Americas | Utaswako Afp-L3 | $1,027 | 4 payments
|
| Hologic | None | $700 | 1 payment
|
| Celgene | None | $300 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $300 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | None | $142 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imjudo | $65 | 2 payments
|
| Sobi | Doptelet | $41 | 1 payment
|
| Ultragenyx Pharmaceutical | None | $38 | 1 payment
|
| Eiger Biopharmaceuticals | Zokinvy | $23 | 1 payment
|
2021: $127,973
| Gilead Sciences | Vemlidy | $70,807 | 51 payments
|
| Intercept Pharmaceuticals | Ocaliva | $24,178 | 19 payments
|
| AbbVie | Mavyret | $9,693 | 13 payments
|
| Pfizer | None | $6,300 | 1 payment
|
| Genentech USA | Tecentriq | $5,092 | 3 payments
|
| Eisai | Lenvima | $4,006 | 3 payments
|
| DiaSorin | None | $3,200 | 1 payment
|
| Echosens North America | Fibroscan | $2,066 | 4 payments
|
| FUJIFILM Healthcare Americas | Utaswako Afp-L3 | $1,800 | 3 payments
|
| Abbott Laboratories | Id Now Instrument | $792 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Yervoy | $38 | 2 payments
|
2020: $168,217
| Gilead Sciences | Epclusa | $76,874 | 51 payments
|
| Intercept Pharmaceuticals | Ocaliva | $40,379 | 24 payments
|
| AbbVie | Mavyret | $16,073 | 16 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $14,195 | 12 payments
|
| Echosens North America | Fibroscan | $9,250 | 4 payments
|
| Merck Sharp & Dohme | None | $4,150 | 3 payments
|
| Eisai | Lenvima | $3,150 | 2 payments
|
| DiaSorin | None | $3,000 | 1 payment
|
| FUJIFILM Medical Systems USA | Wako Hcc Biomarker(S) Dcp and Afp-L3 | $750 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $263 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $134 | 2 payments
|
2019: $306,767
| Gilead Sciences | Epclusa | $124,238 | 96 payments
|
| AbbVie | Mavyret | $77,135 | 76 payments
|
| Intercept Pharmaceuticals | Ocaliva | $60,188 | 40 payments
|
| Eisai | Lenvima | $10,130 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $10,105 | 6 payments
|
| Dova Pharmaceuticals | Doptelet | $9,118 | 9 payments
|
| Genentech USA | Tecentriq | $5,090 | 5 payments
|
| GlaxoSmithKline | None | $2,975 | 3 payments
|
| Abbott Laboratories | Architect System | $2,602 | 7 payments
|
| FUJIFILM Wako Diagnostics U.S.A. | Wako Hcc Biomarker(S) Dcp and Afp-L3 | $2,474 | 4 payments
|
| Janssen Global Services | None | $840 | 1 payment
|
| Shionogi | Mulpleta | $750 | 1 payment
|
| Dynavax Technologies | Heplisav-B | $610 | 1 payment
|
| Merck Sharp & Dohme | None | $364 | 3 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $79 | 1 payment
|
| Biocompatibles | Therasphere-Bio | $68 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2025 | This clinician | $10,200 |
| Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2024 | This clinician | $6,900 |
| Takeda Pharmaceuticals U.S.A., Inc. · Study To Check the Safety of Fazirsiran and Learn If Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due To An Abnormal Version of Alpha-1 Antitrypsin Protein · 2023 | This clinician | $4,500 |
| EIGER BIOPHARMACEUTICALS, INC. · 2021 | Their institution | $350 |
Professional record
- NPI
- 1548281322
- Licence
- CA G45632California G45632: Current · expires 2028-09-30
- Trained
- University of Kansas School of Med (Kc/Wich/Sal), 1980
- Group
- Gastroenterology Medical Clinic · Providence Medical Foundation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G456320
- Taxonomy
- Federal specialty code 207RI0008X (207RI0008X); Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 207RT0003X (207RT0003X)
- Mailing address
- 6022 La Jolla Mesa Dr, La Jolla, CA, 92037
- NPI first listed
- 2006-07-21
- NPI last updated
- 2026-02-25
- NPI record certified
- 2026-02-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 901 Rancho Ln Ste 250, Las Vegas, NV, 89106 · 231 Oconnor Dr, San Jose, CA, 95128 · 2331 Montpelier Dr Ste B, San Jose, CA, 95116
This office lists an electronic records connection.